BLYS

proteins for the treatment of immune deficiency syndromes, cancer, AIDS, infectious diseases, allergies, asthma and autoimmunity; nucleic acids for the treatment of immune deficiency syndromes, cancer, AIDS, infectious diseases, allergies, asthma and autoimmunity; pharmaceutical preparations containing proteins for the treatment of immune deficiency syndromes, cancer, AIDS, infectious diseases, allergies, asthma and autoimmunity; pharmaceutical preparations containing nucleic acids for the treatment of immune deficiency syndromes, cancer, AIDS, infectious diseases, allergies, asthma and autoimmunity; proteins for the enhancement of B cell activity and immunoglobulin production following organ transplant, bone marrow transplant, vaccine administration, immunosuppression, chemotherapy, radio therapy, antibiotic therapy, and gene therapy; nucleic acids for the enhancement of B cell activity and immunoglobulin production following organ transplant, bone marrow transplant, vaccine administration, immunosuppression, chemotherapy, radio therapy, antibiotic therapy, and gene therapy; pharmaceutical preparations containing proteins for the enhancement of B cell activity and immunoglobulin production following organ transplant, bone marrow transplant, vaccine administration, immunosuppression, chemotherapy, radio therapy, antibiotic therapy, and gene therapy; and pharmaceutical preparations containing nucleic acids for the enhancement of B cell activity and immunoglobulin production following organ transplant, bone marrow transplant, vaccine administration, immunosuppression, chemotherapy, radio therapy, antibiotic therapy, and gene therapy